Client Challenge

A vaccine developer needed a way to screen for bacteriophage contamination in cell banks derived from a slow-growing, pathogenic organism. Because of biosafety constraints and the organism’s growth kinetics, direct testing using the pathogen itself wasn’t practical for routine contamination screening. A validated phage detection method that used a safe, well-characterized surrogate host was needed.

Avance Biosciences’ Solution

Avance Biosciences adapted an established bacteriophage detection procedure, originally validated for faster-growing organisms, to work with a non-pathogenic, biosafety-level-1 surrogate host that shares the target pathogen’s core cellular physiology. The development approach:

  • Selected a standardized reference strain, recognized across major pharmacopeias, as the analytical surrogate host based on genetic conservation and established cross-genus host-range patterns in phage infectivity
  • Established a Master Cell Bank and Working Cell Bank from the surrogate host to provide consistent, traceable material for all downstream testing
  • Adapted the double agar overlay method to the surrogate host’s growth characteristics, optimizing culture conditions, phage adsorption timing, and incubation parameters
  • Tested the adapted method with serial dilutions of a positive control phage strain, spanning a range from high titer to single plaques
  • Confirmed that host-only negative controls produced no plaques, while positive controls produced expected plaques across all dilutions
  • Established reproducibility by running the method multiple times with consistent results and verification by independent operators

Assay Development Results

  • System performance: Host-only negative controls reliably produced zero plaques; positive controls at the undiluted titer produced plaques too numerous to count ( excellent titer); serial 10-fold dilutions produced expected countable plaques per plate, demonstrating clear dose-response and plaque clarity.
  • Method robustness: The adapted double agar overlay procedure was successfully transferred to the surrogate host system with all acceptance criteria met on the first development run.
  • Documentation: All method steps, materials, acceptance criteria, and results recorded in a signed development report.

Customer Outcome

  • A pharmacopeia-aligned bacteriophage detection method suitable for routine use with a safe surrogate host
  • Established cell bank materials (Master Cell Bank and Working Cell Bank) from the surrogate host for consistency and traceability
  • Standardized protocol documented and ready for application to future cell bank contamination screening
  • A signed assay development report establishing proof of concept

Client Impact

The client now has a safe, scalable method for detecting lytic and lysogenic bacteriophage contamination in cell banks derived from the slow-growing pathogen, enabling routine quality control screening without biosafety complexity.

Related Services / Technologies

Need a bacteriophage detection method for your cell banks?

CONTACT US